Printer Friendly

Susceptibility of carrion crows to experimental infection with lineage 1 and 2 West Nile viruses.

West Nile virus (WNV), a flavivirus (family Flaviviridae) transmitted by mosquitoes, uses birds as its primary vertebrate reservoir host. WNV has an extensive geographic range that includes Europe, Africa, the Middle East, southern Asia, and Australia (1). In 1999, WNV emerged in North America, where it was first detected in New York, New York. The virus subsequently spread rapidly across the continent, becoming the leading cause of arboviral encephalitis in humans and horses (2), and it was associated with deaths among at least 326 bird species (3). High death rates are most frequently observed among passeriform birds, of which the family Corvidae comprises the most highly susceptible species to WNV (4). In particular, deaths among the American crow (Corvus brachyrhynchos) have been used to track the spread of the virus across many parts of North America (5-8).

Since 2008, WNV has been responsible for outbreaks throughout central and southeastern Europe, affecting countries such as Greece, Italy, Hungary, Romania, and Croatia and constituting a serious veterinary and public health problem. Fatalities have been reported among wild birds in Europe, such as eagles (9,10), sparrow hawks, goshawks, geese, and falcons (11-13). However, death rates among birds in Europe have been low, and no clustered death events have occurred, even when cases were associated with outbreaks of severe human and equine WNV infections (14-17). Several theories have been proposed to explain the low death rates among birds in Europe: limited or insufficient monitoring of deaths among wild birds in Europe; development of immunity among birds from infections acquired on wintering grounds (18); and circulation of WNV strains in Europe with reduced virulence for birds.

Experimental infection of American crows with the North American genotype of WNV (NY99) has shown that the strain has a highly pathogenic phenotype: viremia titers exceeded 9 [log.sub.10] PFU/mL, and all infected birds died (19-23). However, the lack of WNV-associated bird deaths in Europe suggests that European birds might not be susceptible to WNV or that WNV strains from Europe are not virulent to birds. Thus, we evaluated the susceptibility of the European equivalent of the American crow, carrion crows (Corvuscorone), which are ubiquitously present across Europe, by injecting them with selected strains of WNV circulating in Europe and with the prototypic NY99 strain. In addition, we inoculated American crows with a selection of these viruses to assess and compare the virulence of WNV strains from Europe in a bird species known to be highly susceptible to WNV. Susceptibility was assessed in terms of death, survival time, magnitude and duration of viremia, and spread of virus to different organs.

Materials and Methods

Source of Virus and Birds

Five different WNV strains were used in this study: lineage 1a strain NY99-4132 (NY-99) (20); lineage 2 strain Nea Santa-Greece-2010 (Greece-10; GenBank accession no. HQ537483.1) (24); lineage 1a strain Italy/2009/FIN (FIN; GenBank accession no. KF234080); lineage 1a strain Ita09 (GenBank accession no. GU011992.2) (25); and lineage 2 strain 578/10 (GenBank accession no. KC496015). Further details about these viruses are provided in Table 1.

Carrion crows were captured by using walk-in traps in the municipality of Rotterdam, the Netherlands, and then transported to indoor housing at the animal holding facilities at the National Institute for Public Health and the Environment, Bilthoven, the Netherlands. After being inoculated with WNV, the crows were cared for in groups of 8 in isolators under negative pressure. Only seronegative birds were used in this study. Seronegativity was determined by using a neutralization assay (online Technical Appendix,

American crows were captured by using cannon net traps in Bellvue, Colorado, USA; the National Wildlife Diseases Program, Animal and Plant Health Inspection Service, United States Department of Agriculture, assisted with the captures. The crows were banded and transported to Fort Collins, Colorado, where they were housed in 1-[m.sup.3] cages (2 birds per cage) at the Colorado State University Animal Disease Laboratory.

Experimental Infection and Sampling Protocol

Crows were subcutaneously inoculated in the thigh or breast region with 2,000 50% tissue culture infectious doses ([TCID.sub.50]) of virus per 0.1 mL of serum-free Dulbecco's Modified Eagle Medium (DMEM) (Lonza Benelux BV, Breda, the Netherlands). Carrion crows (8 per virus) were injected with WNV strain NY99, Greece-10, FIN, Ita09, or 578/10. American crows were inoculated with NY99 (n = 6), FIN (n = 5), or Ita09 (n = 5). Approximately 0.1 mL of blood was collected from carrion crows at 2-day intervals, up to 8 days postinoculation (dpi), and 0.2 mL of blood was collected from American crows at the same time points and added to 0.9 mL of serum-free DMEM. Coagulated blood from carrion crows was centrifuged at 1,300 x g for 5 min in MiniCollect vials (Greiner Bio-One, Alphen aan den Rijn, the Netherlands) to separate serum, and coagulated blood from American crows was centrifuged at 3,700 x g for 10 min to pellet clotted cells. Serum samples were stored at -80[degrees]C until further use.

Crows were examined for clinical signs twice daily for 14 dpi and euthanized under isoflurane anesthesia upon display of clinical signs. In addition, 2 birds per group of the carrion crows were euthanized at 4 dpi.

Necropsies were performed on all euthanized carrion crows; heart, liver, spleen, kidney, bone marrow, and brain samples were collected. A small section of each tissue was collected, weighed, and homogenized by using a metal bead in 1 mL of DMEM containing 100 U penicillin and 100 [micro]g/mL streptomycin. The remaining portion of the tissues was collected in formalin for use in immunohistochemical staining.

Determination of Virus Loads

We used quantitative real-time reverse transcription PCR (qRT-PCR) to determine virus titers in serum and tissue samples and [TCID.sub.50] titration to calculate infectious virus titers in serum only. In brief, RNA was isolated from 50 [micro]L of serum or 100 [micro]L of homogenized tissue by using the MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche, Almere, the Netherlands) and a MagNA Pure LC automated nucleic acid robotic workstation (Roche) according to the manufacturer's instructions, and subsequently stored at -80[degrees]C. RNA copy numbers were quantified by using unmodified primers as previously described (26). The limit of detection of the assay was 9 (1.0 [log.sub.10]) RNA copies.

After [log.sub.10] titration of serum samples on Vero E6 cells, cytopathic effect was determined at 5 dpi and [TCID.sub.50] infectious titers were calculated by using the Spearman-Karber method (27,28). An initial 1:10 dilution of serum resulted in a limit of detection of [10.sup.1.8] [TCID.sub.50]/mL.


Paraffin sections (4-pm thick) of sagittal organ were processed for streptavidin-biotin-peroxidase immunohistochemical detection of nonstructural protein (NS) 3 antigen. Sections were deparaffinized in xylene, rehydrated in descending concentrations of ethanol, and incubated for 10 min in 3% [H.sub.2][O.sub.2] diluted in PBS to block endogenous peroxidase activity. Antigen exposure was performed by incubation at 121[degrees]C for 15 min in citrate buffer (10 mmol/L, pH 6.0). Sections were subsequently incubated overnight at 4[degrees]C with polyclonal goat anti-WNV NS3 protease (1:100; R&D Systems, Abingdon, UK) or isotype control (goat serum, 1:100; Dako, Eindhoven, the Netherlands) and then detected with polyclonal rabbit anti-goat IgG/HRP (Dako) antibody. Sections were counterstained with Mayer hematoxylin, mounted with Kaiser glycerin-gelatin, and analyzed by using a light microscope.

Statistical Analyses

Survival curves were analyzed by using the log-rank (Mantel-Cox) test. Statistical analyses between >2 groups were performed by using Kruskal-Wallis 1-way analysis of variance; any significant differences were more closely analyzed between the groups by using the Mann-Whitney U test. A Bonferroni correction was applied to each p value, according to the number of comparisons (corrected p value of 0.05/10 = 0.005 for carrion crow peak viremia and organs of carrion crows euthanized on day 4; corrected p value of 0.05/6 = 0.008 for American crow peak viremia and organs of carrion crows euthanized due to illness). For all comparisons, each group had 6 crows, except for American crow groups that received FIN or Ita09 (n = 5).


Illness and Death

Signs of illness (e.g., lethargy, unresponsiveness, anorexia, and ruffled feathers) were observed among most crows within 9 dpi. All 6 carrion crows inoculated with Greece-10 or Ita09 died, and 5 (83%) of the 6 inoculated with NY99 or 578/10 died. All 6 carrion crows inoculated with strain FIN survived (Table 2). Survival curves of the infected birds showed a significant difference in survival between carrion crows infected with Ita09, Greece-10, NY99, or 578/10 and those infected with FIN (p = 0.005) (Figure 1). The median day of death was 7 dpi for carrion crows that died from infection with NY99, Greece-10, or Ita09 and 8 dpi for birds that died from infection with 578/10. All American crows inoculated with NY99 (n = 6) or Ita09 (n = 5) died, and all 5 crows inoculated with FIN survived (Table 3).

Viremia Profiles

WNV viremia profiles were determined in terms of viral

RNA (Table 2; Figure 2) and infectious virus titers in serum (Table 2; Figure 3) of infected carrion crows. In strain NY99-infected birds, the median peak viral RNA titer was 1087 RNA copies/mL of serum (range [10.sup.1] - [10.sup.10.0] [nontransformed values]), and the median peak infectious virus titer was 1074 [TCID.sub.50]/mL of serum (range 1018-1088); these values include 1 bird in which detectable viremia did not develop during the entire course of infection. The median peak viremia titer for Greece-10-infected birds was [10.sup.10.3] RNA copies/mL of serum (range [10.sup.9.8] - [10.sup.11.7]) and [10.sup.7.8] [TCID.sub.50]/mL of serum (range [10.sup.7.3] - [10.sup.9.8]). FIN-infected birds had median peak viremia titers of 102.7 RNA copies/mL of serum (range [10.sup.1] - [10.sup.5.9]) and [10.sup.1.8] [TCID.sub.50]/mL of serum (range [10.sub.1.8] - [10.sup.2.5]); however, viremia was detectable in only 3 of 6 birds, and infectious virus could be isolated from only 1 bird. The median peak viremia titers for Ita09-infected birds were [10.sup.9.7] RNA copies/mL of serum (range [10.sup.8.0] - [10.sup.10.0]) and [10.sup.7.6] [TCID.sub.50]/mL of serum (range [10.sub.6.3] - [10.sup.8.8]). Birds infected with strain 578/10 had median peak viremia titers of [10.sup.8.4] RNA copies/mL of serum (range [10.sup.6.0] - [10.sup.10.1]) and [10.sup.5.1] [TCID.sub.50]/mL of serum (range [10.sup.2.8] - [10.sup.8.5]).

Strain Greece-10-infected birds had median peak viral RNA titers significantly higher than those for NY99-infected (p = 0.004), FIN-infected (p = 0.005), and 578/10-infected (p = 0.004) birds. Greece-10-infected birds also had median infectious virus titers significantly higher than those for FIN-infected birds (p = 0.003), but FIN-infected birds had RNA and infectious titers lower than those for Greece-10-infected (p = 0.005 and 0.003, respectively), Ita09-infected (p = 0.005 and 0.002, respectively), and 578/10-infected (p = 0.005 and 0.002, respectively) crows.

Viremia profiles were also determined for American crows infected with 3 of the 5 different WNV strains (Table 3). NY99-infected birds had median peak viremia titers of [10.sup.9.6] RNA copies/mL of serum (range [10.sup.9.1] - [10.sup.10.1]) and [10.sup.7.2] [TCID.sub.50]/mL of serum (range [10.sup.4.7] - [10.sup.7.2]). Detectable viremia developed in only 2 of the 5 FIN-infected birds, resulting in median peak viremia titers of [10.sup.1.0] RNA copies/mL of serum (range [10.sup.1] - [10.sup.6.9]) and [10.sup.1.8] [TCID.sub.50]/mL of serum (range [10.sup.1.8] - [10.sup.2.7]). Median peak viremia titers for Ita09-infected birds were [10.sup.8.8] RNA copies/mL of serum (range [10.sup.8.0] - [10.sup.9.1]) and [10.sup.6.7] [TCID.sub.50]/mL of serum (range [10.sup.6.0] - [10.sup.7.5]). American crows infected with strain NY99 had the highest median peak viral RNA and infectious virus titers, and FIN-infected birds had the lowest median titers (significant only when compared with each other: p = 0.008 and 0.006, respectively).

Tissue Tropism

Virus loads were determined in the heart, liver, spleen, kidney, bone marrow, and brain of all birds. To assess the spread of virus to the different organs at the approximate peak of viremia, we euthanized 2 birds per group at 4 dpi. Virus was detected in all organs from these birds. On average, the highest viral RNA titers were detected in the liver, followed by the bone marrow, spleen, kidney, and heart; the lowest titers were found in the brain (Figure 4). Between the different virus strains, viral RNA titers were the highest in the organs of birds infected with strain Greece-10 or 578/10, followed by NY99 and Ita09; titers were significantly higher than those for birds infected with strain FIN (p = 0.005 for all). Virus distribution in FIN-infected birds was not consistent; viral RNA was undetectable in the bone marrow and brain of both birds tested on 4 dpi, and for 1 of these birds, viral RNA was also undetectable in the spleen.

Birds euthanized because of illness had virus present in all organs; in most cases, the spleen, liver, and bone marrow contained the highest average viral RNA load, followed by kidney and heart; the lowest average viral RNA titers were in the brain. Viral RNA titers in organs of Greece-10-infected birds were higher than those in organs of birds infected with the other viruses, but this observation was not statistically significant (Figure 5).

The 1 NY99-infected and 3 FIN-infected survivor birds that were free of viremia throughout the 8 days of blood sampling underwent necropsy at 14 dpi. Of interest, virus was present in all organs of the NY99-infected bird (median virus load of [10.sup.3.1] RNA copies/g of tissue) and in at least 3 of the 6 organs from FIN-infected birds (median virus load of [10.sup.2.0] RNA copies/g of tissue), showing that these birds did undergo productive WNV infection.


Sections of organs from 2 birds necropsied at 4 dpi were stained with polyclonal anti-WNV NS3 to confirm replication of virus in the tissues and to exclude positive qRTPCR detection due to spillover from blood at the approximate peak of viremia. Tissues most consistently positive for WNV antigen were the liver (80%), kidney (80%), bone marrow (80%), and spleen (78%); tissues least consistently positive for WNV antigen were heart (50%) and brain (10%) (Table 4). However, in terms of virus load, antigen was most abundant in the liver, bone marrow, and spleen. Overall, at 4 dpi, organs of birds most positive and most abundant for viral antigen were those infected by strains 578/10 and Greece-10, followed by NY99 and Ita09. The organs of FIN-infected birds were all negative for virus antigen at this time point.


In this study, we assessed the susceptibility of carrion crows to different strains of WNV. First we demonstrated that carrion crows are susceptible to WNV infection by using the North American strain NY99, which has previously been shown to be highly virulent in American crows (19-23). In agreement with the findings in those studies, our results showed that infection of carrion crows with NY99 resulted in high viremia titers and death. In addition, virus had disseminated to the organs of infected birds by 4 dpi, further demonstrating the susceptibility of carrion crows to WNV infection, which appears to be very similar to that of American crows.

Next we studied the susceptibility of carrion crows to selected strains of WNV from Europe. We found that carrion crows are highly susceptible to infection with both lineage 1 and 2 WNV strains from Europe. In addition, we showed that susceptibility is strain-dependent. Of the 5 WNV strains tested, 4 led to death for 83%-100% of infected birds and to high viremia titers and abundant antigen in the organs of euthanized birds; however, birds inoculated with FIN did not die from infection, and they had relatively low virus titers in the blood and no viral antigen in the organs at 4 dpi. A previous study describing the inoculation of carrion crows with WNV strains from France (Fr2000) and Israel (Is98) also suggested that carrion crows are susceptible to infection with WNV in a strain-dependent manner (29). The study showed death rates of 33% (Fr2000) and 100% (Is98) from the 2 strains, and viral RNA loads in serum, oral swab samples, and feathers of Is98-infected birds were higher than those of Fr2000-infected birds (29). Thus, WNV strains FIN and Fr2000 show a similar attenuation in carrion crows.

To more accurately assess the virulence of WNV strains from Europe, we inoculated American crows, a bird species known to be highly susceptible to WNV, with 2 of the 4 strains from Europe (Ita09 and FIN) and with strain NY99 from North America. Similar to what was seen with carrion crows, American crows infected with Ita09 had high peak viremia titers, and all succumbed to the infection, whereas those infected with FIN had low viremia titers, and all survived infection. Furthermore, it was demonstrated that the Greece-10 strain used in this study was also 100% lethal in American crows (A.C. Brault et al., unpub. data). In fact, American crows infected with Greece-10 (vs. the other strains used in this study) had the highest median peak viremia titers in terms of RNA and infectious virus (data not shown). These results show that in American crows, WNV strains (apart from FIN) from Europe are as virulent as the prototypic NY99 strain from North America.

The fact that susceptibility of birds to WNV can be strain-dependent was clearly demonstrated by the attenuated virulence phenotype of WNV strain FIN in carrion and American crows (this study) and in European jackdaws (30); FIN-infected crows consistently exhibited an absence of death, lower peak viremia titers, and less dissemination of virus to the organs at the approximate peak of viremia. A previous study showed that the introduction of a P249T amino acid substitution in the NS3 helicase of North Amercan strain NY99 led to a highly attenuated phenotype, whereas a T249P substitution introduced in a low-virulence WNV strain resulted in a phenotype highly virulent to American crows (22). Four virus strains used in this study contain a proline at NS3-249, whereas FIN contains a threonine at this position (37). It is therefore likely that the attenuated phenotype of FIN is a result of this threonine amino acid at NS3-249, a mutation that could be relevant for at least 3 different species of birds in the family Corvidae. Studies in North American and European corvids are ongoing in order to test the relevance of the T249P substitution and several other mutations when introduced into the genome of WNV-FIN.

We have shown that bird susceptibility to WNV can be strain-dependent. However, susceptibility is also clearly related to host factors. As a whole, jackdaws were less susceptible than the carrion crows to the same selection of otherwise highly virulent WNV strains, and they had lower death rates and virus loads in blood and organs (30). Species susceptibility has been shown to differ within various avian families (7), including birds in the family Corvidae, of which, for example, the fish crow (Corvus ossifragus) was less susceptible to lethal WNV infection (23). Although the reasons for this varied susceptibility are not well understood, potential contributing factors may include host traits, such as genetic composition, immune response, and physiologic mechanisms (23).

A measure of the potential for transmission of virus to feeding mosquitoes is the level of infectious virus titers produced during viremia. The median peak serum titer of infectious virus was highest in Greece-10-infected carrion crows and lowest in FIN-infected carrion crows. Studies have shown that WNV titers of >[10.sup.5] PFU/mL were considered infectious for Culex pipiens (32) and Cx. quinquefasciatus (33) mosquitoes. Considering this cutoff of [10.sup.5] PFU/mL or of [10.sup.5.2] [TCID.sub.50]/mL, according to a conversion factor of 1 [TCID.sub.50] to 0.7 PFU (34), infectious titers obtained for carrion crows infected with Greece-10, Ita09, or NY99 would be sufficient for efficient transmission of virus to feeding mosquitoes. Carrion crows infected with strain 578/10 had median peak viremia titers slightly below this threshold ([10.sup.5.1] [TCID.sub.50]/mL; Table 2), suggesting that the carrion crow may not be an efficient amplifier for this WNV strain. However, a possible explanation for the apparent low viremia titers in 578/10-infected birds could be that blood sampling was conducted on alternate days, possibly missing higher peak viremia titers of infectious virus. For the American crows, median peak viremia titers for Ita09 (Table 3) were slightly lower than those for carrion crows (Table 2). However, serum samples from American crows underwent 2 repeated freeze-thaw cycles, which could have resulted in the detection of lower infectious virus titers. Nonetheless, these results show that WNV strains from Europe can produce viremia titers in American crows that could be sufficient for efficient transmission to feeding mosquitoes. Nevertheless, reservoir competence studies involving the feeding of European mosquitoes on viremic WNV-infected carrion crows are needed to determine whether the carrion crow could indeed be a potential reservoir host and contributor to the WNV transmission cycle.

We have shown that carrion crows, a species of bird ubiquitously found across Europe, are highly susceptible to WNV strains currently circulating in Europe. These birds could therefore potentially be useful as part of dead bird surveillance in the early detection of WNV in Europe. Future studies assessing the susceptibility of the closely related hooded crow (Corvus cornix) to WNV may also prove to be insightful, as this is the more predominant corvid species in eastern and southeastern Europe, where WNV is more common. The susceptibility of European birds to WNV has been demonstrated in multiple studies (9,10,12,13,29,30,35-38), however, it is peculiar that the number of WNV-associated deaths among birds in Europe is not as extensive as that among birds in North America. Possible explanations may be a lower reporting of bird deaths in Europe as compared with that in the United States or that other ecologic factors, such as mosquito competence, abundance, distribution or behavior, exert a limiting effect on the transmission of WNV in Europe.

Author affiliations: Erasmus Medical Center, Rotterdam, the Netherlands (S.M. Lim, G. van Amerongen, V.D. Sewbalaksing, A.D.M.E. Osterhaus, P. Koraka, B.E.E. Martina); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (A.C. Brault, A.M. Bosco-Lauth, H. Romo); Colorado State University, Fort Collins (R.A. Bowen); Artemis One Health Research Institute, Utrecht, the Netherlands (A.D.M.E. Osterhaus, P. Koraka, B.E.E. Martina)



We thank Vittorio Sambri, Luisa Barzon, Giorgio Palu, and Tamas Bakonyi for providing the low-passage isolates used in this study. We also thank Tanja Schouten and Angela Gomersbach for their excellent technical assistance; Jeroen Roose and Peter van Run for their technical assistance with the immunohistochemistry; and Thijs Kuiken for his assistance with the analysis of the histological stainings.

The research leading to these results has received complete funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under the project "VECTORIE," European Commission grant agreement number 261466. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Trapping of carrion crows was performed with the assistance of the Gemeentewerken Rotterdam under permission obtained from the Ministry of Agriculture (registered under no. FF/75A/2011/031). Experimental inoculations were performed under protocol number 122-12-12 with permission obtained from the Animal Ethics Committee of Erasmus Medical Centre. All efforts were made to minimize animal suffering. Trapping of American crows was performed with the assistance of Todd Felix under US Fish and Wildlife Scientific Collecting Permit number MB-91672A. Experimental inoculations of crows were performed under Colorado State University IACUC approval number 10-2078A.

Ms. Lim is a graduate student at the department of Viroscience of the Erasmus Medical Centre. Her research interests include the pathogenesis of (neurotropic) arboviruses.


(1.) Hayes CG. West Nile Fever. In: Monath TP, editor. The arboviruses: epidemiology and ecology, vol. 5. Boca Raton (FL): CRC Press; 1989. p. 59-88.

(2.) O'Leary DR, Marfin AA, Montgomery SP, Kipp AM, Lehman JA, Biggerstaff BJ, et al. The epidemic of West Nile virus in the United States. 2002. Vector Borne Zoonotic Dis. 2004;4:61-70.

(3.) Centers for Disease Control and Prevention. Guidelines for surveillance, prevention, and control of West Nile virus infection-United States. JAMA. 2000;283:997-8.

(4.) Wheeler SS, Barker CM, Fang Y, Armijos MV, Carroll BD, Husted S, et al. Differential impact of West Nile virus on California birds. Condor. 2009;111:1-20. 10.1525/cond.2009.080013

(5.) Eidson M, Schmit K, Hagiwara Y, Anand M, Backenson PB, Gotham I, et al. Dead crow density and West Nile virus monitoring, New York. Emerg Infect Dis. 2005;11:1370-5.

(6.) Julian KG, Eidson M, Kipp AM, Weiss E, Petersen LR, Miller JR, et al. Early season crow mortality as a sentinel for West Nile virus disease in humans, northeastern United States. Vector Borne Zoonotic Dis. 2002;2:145-55. 10.1089/15303660260613710

(7.) McLean RG. West Nile virus in North American birds. Ornithological Monographs. 2006;60:44-64. 10.1642/0078-6594(2006)60[44:WNVINA]2.0.C0;2

(8.) Reisen WK, Barker CM, Carney R, Lothrop HD, Wheeler SS, Wilson JL, et al. Role of corvids in epidemiology of West Nile virus in southern California. J Med Entomol. 2006;43:356-67.

(9.) Hofle U, Blanco JM, Crespo E, Naranjo V, Jimenez-Clavero MA, Sanchez A, et al. West Nile virus in the endangered Spanish imperial eagle. Vet Microbiol. 2008;129:171-8. 10.1016/j.vetmic.2007.11.006

(10.) Jimenez-Clavero MA, Sotelo E, Fernandez-Pinero J, Llorente F, Blanco JM, Rodriguez-Ramos J, et al. West Nile virus in golden eagles, Spain, 2007. Emerg Infect Dis. 2008;14:1489-91.

(11.) Bakonyi T, Ferenczi E, Erdelyi K, Kutasi O, Csorgo T, Seidel B, et al. Explosive spread of a neuroinvasive lineage 2 West Nile virus in central Europe, 2008/2009. Vet Microbiol. 2013;165:61-70.

(12.) Bakonyi T, Ivanics E, Erdelyi K, Ursu K, Ferenczi E, Weissenbock H, et al. Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe. Emerg Infect Dis. 2006; 12:618-23.

(13.) Wodak E, Richter S, Bago Z, Revilla-Fernandez S, Weissenbock H, Nowotny N, et al. Detection and molecular analysis of West Nile virus infections in birds of prey in the eastern part of Austria in 2008 and 2009. Vet Microbiol. 2011;149:358-66.

(14.) Calistri P, Giovannini A, Savini G, Monaco F, Bonfanti L, Ceolin C, et al. West Nile virus transmission in 2008 in north-eastern Italy. Zoonoses Public Health. 2010;57:211-9.

(15.) Dauphin G, Zientara S, Zeller H, Murgue B. West Nile: worldwide current situation in animals and humans. Comp Immunol Microbiol Infect Dis. 2004;27:343-55. 10.1016/j.cimid.2004.03.009

(16.) Jourdain E, Schuffenecker I, Korimbocus J, Reynard S, Murri S, Kayser Y, et al. West Nile virus in wild resident birds, southern France, 2004. Vector Borne Zoonotic Dis. 2007;7:448-52.

(17.) Valiakos G, Touloudi A, Iacovakis C, Athanasiou L, Birtsas P, Spyrou V, et al. Molecular detection and phylogenetic analysis of West Nile virus lineage 2 in sedentary wild birds (Eurasian magpie), Greece, 2010. Euro Surveill. 2011;16:pii:19862.

(18.) Hubalek Z, Halouzka J. West Nile fever--a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis. 1999;5:643-50.

(19.) Komar N, Langevin S, Hinten S, Nemeth N, Edwards E, Hettler D, et al. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg Infect Dis. 2003;9:311-22.

(20.) Brault AC, Langevin SA, Bowen RA, Panella NA, Biggerstaff BJ, Miller BR, et al. Differential virulence of West Nile strains for American crows. Emerg Infect Dis. 2004;10:2161-8.

(21.) Weingartl HM, Neufeld JL, Copps J, Marszal P. Experimental West Nile virus infection in blue jays (Cyanocitta cristata) and crows (Corvus brachyrhynchos). Vet Pathol. 2004;41:362-70.

(22.) Brault AC, Huang CY, Langevin SA, Kinney RM, Bowen RA, Ramey WN, et al. A single positively selected West Nile viral mutation confers increased virogenesis in American crows. Nat Genet. 2007;39:1162-6.

(23.) Nemeth NM, Thomsen BV, Spraker TR, Benson JM, Bosco-Lauth AM, Oesterle PT, et al. Clinical and pathologic responses of American crows (Corvus brachyrhynchos) and fish crows (C. ossifragus) to experimental West Nile virus infection. Vet Pathol. 2011;48:1061-74.

(24.) Papa A, Xanthopoulou K, Gewehr S, Mourelatos S. Detection of West Nile virus lineage 2 in mosquitoes during a human outbreak in Greece. Clin Microbiol Infect. 2011;17:1176-80.

(25.) Barzon L, Franchin E, Squarzon L, Lavezzo E, Toppo S, Martello T, et al. Genome sequence analysis of the first human West Nile virus isolated in Italy in 2009. Euro Surveill. 2009;14:pii:19384.

(26.) Lim SM, Koraka P, Osterhaus AD, Martina BE. Development of a strand-specific real-time qRT-PCR for the accurate detection and quantitation of West Nile virus RNA. J Virol Methods. 2013;194:146-53.

(27.) Spearman C. The method of right and wrong cases (constant stimuli) with Gauss formulae. Br J Psychol. 1908;2:227-42.

(28.) Karber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmakol. 1931;162:480-3.

(29.) Dridi M, Vangeluwe D, Lecollinet S, van den Berg T, Lambrecht B. Experimental infection of carrion crows (Corvus corone) with two European West Nile virus (WNV) strains. Vet Microbiol. 2013;165:160-6. j.vetmic.2012.12.043

(30.) Lim SM, Brault AC, van Amerongen G, Sewbalaksing VD, Osterhaus AD, Martina BE, et al. Susceptibility of European jackdaws (Corvus monedula) to experimental infection with lineage 1 and 2 West Nile viruses. J Gen Virol. 2014;95:1320-9.

(31.) Lim SM, Koraka P, van Boheemen S, Roose JM, Jaarsma D, van de Vijver DA, et al. Characterization of the mouse neuroinvasiveness of selected European strains of West Nile virus. PLoS ONE. 2013;8:e74575. journal.pone.0074575

(32.) Turell MJ, O'Guinn M, Oliver J. Potential for New York mosquitoes to transmit West Nile virus. Am J Trop Med Hyg. 2000;62:413-4.

(33.) Sardelis MR, Turell MJ, Dohm DJ, O'Guinn ML. Vector competence of selected North American Culex and Coquillettidia mosquitoes for West Nile virus. Emerg Infect Dis. 2001;7:1018-22.

(34.) Carter J, Saunders VA. Methods used in virology. In: Virology: principles and application. 1st ed. Chichester (UK): Wiley; 2007. p. 9-29.

(35.) Erdelyi K, Ursu K, Ferenczi E, Szeredi L, Ratz F, Skare J, et al. Clinical and pathologic features of lineage 2 West Nile virus infections in birds of prey in Hungary. Vector Borne Zoonotic Dis. 2007;7:181-8.

(36.) Sotelo E, Gutierrez-Guzman AV, del Amo J, Llorente F, El-Harrak M, Perez-Ramirez E, et al. Pathogenicity of two recent western Mediterranean West Nile virus isolates in a wild bird species indigenous to southern Europe: the red-legged partridge. Vet Res. 2011;42:11.

(37.) Ziegler U, Angenvoort J, Fischer D, Fast C, Eiden M, Rodriguez AV, et al. Pathogenesis of West Nile virus lineage 1 and 2 in experimentally infected large falcons. Vet Microbiol. 2013;161:263-73.

(38.) Del Amo J, Llorente F, Figuerola J, Soriguer RC, Moreno AM, Cordioli P, et al. Experimental infection of house sparrows (Passer domesticus) with West Nile virus isolates of Euro-Mediterranean and North American origins. Vet Res. 2014;45:33.

Address for correspondence: Byron E.E. Martina, Department of Viroscience, Erasmus Medical Centre, Postbus 2040, 3000 CA, Rotterdam, the Netherlands; email:

Stephanie M. Lim, Aaron C. Brault, Geert van Amerongen, Angela M. Bosco-Lauth, Hannah Romo, Varsha D. Sewbalaksing, Richard A. Bowen, Albert D.M.E. Osterhaus, Penelope Koraka, [1] Byron E.E. Martina [1]

[1] These authors contributed equally to this article.

Table 1. West Nile virus strains used for susceptibility studies
in carrion and American crows

Strain                        Source                  Passage
                                                     history *

NY99-4132              American crow (brain)            V2
Nea Santa-            Culex pipiens mosquito            V1
Italy/2009/FIN   Human with neuroinvasive disease     V2, C1
Ita09            Human with neuroinvasive disease     V1, C1
578/10                     Horse (brain)              V2, C1

Strain             Location      Genetic     Crow species
                                 lineage      inoculated

NY99-4132        United States     1a      Carrion, American
Nea Santa-          Greece          2           Carrion
Italy/2009/FIN       Italy         1a      Carrion, American
Ita09                Italy         1a      Carrion, American
578/10              Hungary         2           Carrion

* Viruses were propagated in Vero (V) or C6/36 insect cells
(C). Numbers following passage source represent the number
of virus passages.

Table 2. Clinical profile for carrion crows experimentally
infected with various West Nile virus strains *

Virus group      No. died/no.   Day of death,
                  total (%)      median dpi

NY99-4132          5/6 (83)           7
Nea Santa-        6/6 (100)           7
Italy/2009/FIN     0/6 (0)           NA
Ita09             6/6 (100)           7
578/10             5/6 (83)           8

Virus group            Median peak viremia, viral RNA/mL
                            serum (range); no. birds

NY99-4132         [10.sup.8.7] ([10.sup.1.0]-[10.sup.10.0]); 6
Nea Santa-       [10.sup.10.3] ([10.sup.9.8]-[10.sup.11.7]); 6
Italy/2009/FIN    [10.sup.2.7] ([10.sup.1.0]-[10.sup.5.9]); 6
Ita09             [10.sup.9.7] ([10.sup.8.0]-[10.sup.10.0]); 6
578/10            [10.sup.8.4] ([10.sup.6.0]-[10.sup.10.1]); 6

Virus group       Mean duration, d,     Mean day of peak
                 of viremia [+ or -]    viremia [+ or -]
                    SD; no. birds         SD; no. birds
                     ([dagger])            ([dagger])

NY99-4132        5.2 [+ or -] 1.0; 5   4.3 [+ or -] 0.7; 5
Nea Santa-       5.7 [+ or -] 0.7; 6   4.5 [+ or -] 0.9; 6
Italy/2009/FIN   2.7 [+ or -] 0.9; 3   6.7 [+ or -] 0.9; 3
Ita09            6.0 [+ or -] 1.2; 6   4.3 [+ or -] 0.7; 6
578/10           5.7 [+ or -] 1.8; 6   3.5 [+ or -] 0.9; 6

Virus group                  Median peak viremia
                              (range); no. birds
                              ([double dagger])

NY99-4132        [10.sup.7.4] ([10.sup.1.8]-[10.sup.8.8]); 6
Nea Santa-       [10.sup.7.8] ([10.sup.7.3]-[10.sup.9.8]); 6
Italy/2009/FIN   [10.sup.1.8] ([10.sup.1.8]-[10.sup.2.5]); 6
Ita09            [10.sup.7.6] ([10.sup.6.3]-[10.sup.8.8]); 6
578/10           [10.sup.5.1] ([10.sup.2.8]-[10.sup.8.5]); 6

* dpi, days postinoculation; NA, not applicable; [TCID.sub.50],
50% tissue culture infectious dose.

([dagger]) Based on viral RNA titers.

([double dagger]) Viral titers are expressed as [log.sub.10]
[TCID.sub.50]/mL of serum.

Table 3. Clinical profile of American crows experimentally
infected with West Nile virus strains NY99-4132,
Italy/2009/FIN, and Ita09

Virus group       No. died/no.        Median peak viremia,
                   total (%)           viral RNA/mL serum
                                       (range); no. birds

NY99-4132          6/6 (100)     [10.sup.9.6] ([10.sup.9.1] -
                                       [10.sup.10.1]); 6
Italy/2009/F IN     0/5 (0)       [10.sup.1.0] ([10.sup.1.0] -
                                        [10.sup.6.9]); 5
Ita09              5/5 (100)      [10.sup.8.8] ([10.sup.8.0] -
                                        [10.sup.9.1]); 5

Virus group                Median peak
                       viremia, TCID50/mL
                         serum (range);
                           no. birds *

NY99-4132         [10.sup.7.2] ([10.sup.4.7] -
                        [10.sup.7.2]); 6
Italy/2009/F IN   [10.sup.1.8] ([10.sup.1.8] -
                        [10.sup.2.7]); 5
Ita09             [10.sup.6.7] ([10.sup.6.0] -
                        [10.sup.7.5]); 5

* Virus titers are expressed as log10 50% tissue culture
infectious dose (TCID50)/mL of serum.

Table 4. Immunohistochemical analysis of West Nile virus
antigen distribution in experimentally infected carrion
crows euthanized at 4 dpi *

Virus strain,           Heart   Liver   Spleen
bird no.

  1                       -      ++       ++
  7                       -       +       +
Nea Santa-Greece-2010
  1                      +/-     ++       ++
  7                      +/-     ++       ++
  1                       -       -       -
  7                       -       -       -
  1                      +/-     ++       ++
  7                       -      ++       ND
  1                      ++      ++       ++
  7                      +/-     ++       ++
Score per organ          7.0    23.0     20.0
No. positive birds/     5/10    8/10     7/9
  total no. birds

Virus strain,           Kidney    Bone    Brain
bird no.                         marrow

  1                       +        ++       -
  7                      +/-       +        -
Nea Santa-Greece-2010
  1                       +        ++      +/-
  7                       +        ++       -
  1                       -        -        -
  7                       -        -        -
  1                      +/-       +        -
  7                      +/-       +        -
  1                      +/-       ++       -
  7                       +        ++       -
Score per organ          12.0     21.0     1.0
No. positive birds/      8/10     8/10    1/10
  total no. birds

Virus strain,           Total score     Average      No. positive
bird no.                 per bird      score per     organs/total
                                      virus strain    no. organs

NY99-4132                                 9.0
  1                        11.0                          4/6
  7                         7.0                          4/6
Nea Santa-Greece-2010                     12.5
  1                        13.0                          6/6
  7                        12.0                          5/6
Italy/2009/FIN                             0
  1                          0                           0/6
  7                          0                           0/6
Ita09                                     8.0
  1                        10.0                          5/6
  7                         6.0                          3/5
578/10                                    12.5
  1                        13.0                          5/6
  7                        12.0                          5/6
Score per organ
No. positive birds/
  total no. birds

* Subjective determinations of the amount of antigen in
each organ were made: negative (-), minimal (+/-), moderate
(+), or abundant (++). Each determination was given a
score from 0 to 3: negative (0), minimal (1), moderate (2),
and abundant (3). ND = not determined. dpi, days
postinoculation; ND, not determined.
COPYRIGHT 2015 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Lim, Stephanie M.; Brault, Aaron C.; van Amerongen, Geert; Bosco-Lauth, Angela M.; Romo, Hannah; Sew
Publication:Emerging Infectious Diseases
Date:Aug 1, 2015
Previous Article:Differentiation of acute Q fever from other infections in patients presenting to hospitals, the Netherlands.
Next Article:Hospital resource utilization and patient outcomes associated with respiratory viral testing in hospitalized patients.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters